Jim Tananbaum in Support for the Mindstrong Health Platform

Mindstrong Health is a platform that has recently transformed diagnosing and delivering precision therapy. The founding team of Mindstrong Health brings to our knowledge the vital challenges faced by the medical community in delivering care to patients suffering from cognitive health disorder. One of the lead investors of the company is Jim Tananbaum, the CEO and Managing Director of Foresite Capital, who praised the platform for its outstanding services. This is because of the quality care the platform offers to individuals. Mindstrong is an Al-powered platform designed to specifically monitor the patterns of an individual on his/her smart-phone devices in order to measure the brain function. The objective of the platform is to offer a transformative biotechnology in healthcare services. Therefore, the company developed a biomarker panel which includes attention, memory processing speed and executive function.

About Mindstrong Health

The company came up with an outstanding way of keeping track of mental health. This has been a challenging part for the medical community. With Mindstrong’s Technology, it has made it possible to deliver continuous and systematic measurement of behavior and cognition at a precise level of insight and resolution. This remains as a major breakthrough in the medical sector. Previously all modern medicine depended on an objective measurement while Mindstrong depends on keeping a real time data by tracking mental health.

Foresite Capital and ARCH Venture Partners led the round through investing and campaigning for the remarkable platform, and were later joined by Optum Ventures, Berggruen Holdings and the One Mind Brain Health Impact Fund.

About Jim Tananbaum

Besides Jim Tananbaum being the founding CEO of Foresite Capital Management with $1.1 billion in assets management, he has also led investments in 21 successful health companies. According to Inc42, this includes Amira Pharmaceuticals which was later on acquired by Bristol-Myers Squibb, Amerigroup and Pharmaceuticals. Jim had previously founded and held management positions at GelTex Pharmaceuticals which was acquired by Genzyme for $1.6 Billion. Dr. Tananbaum has more than 20 years of experience in building and investing in healthcare companies. Jim Tananbaum is one of the most relevant professionals in the world medical community. This is evident with his level of education. He holds an M.D. from Harvard Medical School, an M.B.A from Harvard Business School, and also attained a B.S. and B.S.E.E from Yale University. He surely is one of the leading figures in the medical community. Read ideamensch’s interview of Mr. Tananbaum here.

Ref: https://www.researchgate.net/profile/Jim_Tananbaum

Leave a Reply

Your email address will not be published. Required fields are marked *